Sign up USA
Proactive Investors - Run By Investors For Investors

Aviragen tanks as trial of asthma treatment flops

Aviragen says its trial of asthma treatment vapendavir has failed to meet its primary endpoint.
Aviragen tanks as trial of asthma treatment flops
Aviragen announces results of vapendavir trial

Aviragen Therapeutics (NASDAQ:AVIR) was on the back foot on Tuesday after reporting “disappointing” results for a trial of its asthma treatment, vapendavir.

The NASDAQ-listed drug maker said the Sptiritus phase 2b trial study of vapendavir in treating moderate to severe asthma sufferers with a rhinovirus infection did not meet its primary endpoint.

The treatment failed to demonstrate a “statistically significant” reduction in asthma symptoms at day 14 of the study for the 264 mg or 528 mg dosages, compared to placebo.

“We are disappointed that the Spirtus trial did not meet its primary endpoint in this patient population,” chief executive Joseph Patti, said.

“There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset of their symptoms, and as such, we plan to take time to fully analyse the data before making a decision on whether to initiate a study in hematopoietic stem cell transplant patients, where the ability to stop the progression of the rhinovirus infection could be beneficial.” 

In early February, Aviragen reported that BTA 585, its drug for the treatment of respiratory syncytial virus infections, flunked in a phase 2a trial.

Shares plunged 34.91% on the NASDAQ in early US trade. 



Register here to be notified of future AVIR Company articles

Related Articles

AZN3.jpg
November 10 2016
Patent safeguards the technology at the heart of the device that offers a non-invasive method of monitoring diabetes.
test tubes in a laboratory
Wed
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
fruit and tape measure, symbolising weight loss
March 08 2017
The City broker says OptiBiotix is “well-positioned” to be a leader in the growing microbiome space
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use